Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Garcia-Alfonso, P; Benavides, M; Falco, E; Munoz, A; Gomez, A; Sastre, J; Rivera, F; Montagut, C; Salgado, M; Lopez-Ladron, A; Lopez, R; de Mena, IR; Duran, G; Aranda, E.

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

ONCOLOGIST. 2018; 23(11): 1271 Nº de citas: 8 [doi:10.1634/theoncologist.2018-0316]

Hodi, FS; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Rutkowski, P; Cowey, CL; Lao, CD; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, PF; Smylie, M; Hill, A; Hogg, D; Marquez-Rodas, I; Jiang, J; Rizzo, J; Larkin, J; Wolchok, JD.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

LANCET ONCOLOGY. 2018; 19(11): 1480-1492 Nº de citas: 1141 [doi:10.1016/S1470-2045(18)30700-9]

Ruiz-Pinto, S; Martin, M; Pita, G; Caronia, D; de la Torre-Montero, JC; Moreno, LT; Moreno, F; Garcia-Saenz, JA; Benitez, J; Gonzalez-Neira, A.

Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial

PHARMACOGENETICS AND GENOMICS. 2018; 28(11): 245-250 Nº de citas: 5 [doi:10.1097/FPC.0000000000000354]

Paumard-Hernandez, B; Calvete, O; Perez, L; Tejero, H; Al-Shahrour, F; Pita, G; Barroso, A; Trivino, J; Urioste, M; Valverde, C; Billalabeitia, E; Quiroga, V; Moreno, JF; Aramburo, A; Lopez, C; Maroto, P; Sastre, J; Fita, MJ; Duran, I; Lorenzo-Lorenzo, I; Iranzo, P; del Muro, X; Ros, S; Zambrana, F; Autran, A; Benitez, J.

Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer

INTERNATIONAL JOURNAL OF CANCER. 2018; 143(8): 1954-1962 Nº de citas: 18 [doi:10.1002/ijc.31604]

Salvador-Martin, S; Garcia-Gonzalez, X; Garcia, MI; Blanco, C; Garcia-Alfonso, P; Robles, L; Gravalos, C; Pachon, V; Longo, F; Martinez, V; Sanjurjo-Saez, M; Lopez-Fernandez, LA.

Clinical utility of ABCB1 for preventing toxicity in treatment with irinotecan

PHARMACOLOGICAL RESEARCH. 2018; 136: 133-139 Nº de citas: 19 [doi:10.1016/j.phrs.2018.08.026]

Collado-Borrell, R; Escudero-Vilaplana, V; Calles, A; Garcia-Martin, E; Marzal-Alfaro, B; Gonzalez-Haba, E; Herranz-Alonso, A; Sanjurjo-Saez, M.

Oncology Patient Interest in the Use of New Technologies to Manage Their Disease: Cross-Sectional Survey

JOURNAL OF MEDICAL INTERNET RESEARCH. 2018; 20(10): Nº de citas: 35 [doi:10.2196/11006]

Martin, M; de la Torre-Montero, JC; Lopez-Tarruella, S; Pinilla, K; Casado, A; Fernandez, S; Jerez, Y; Puente, J; Palomero, I; del Val, RG; del Monte-Millan, M; Massarrah, T; Vila, C; Garcia-Paredes, B; Garcia-Saenz, JA; Lluch, A.

Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

BREAST CANCER RESEARCH AND TREATMENT. 2018; 171(3): 627-634 Nº de citas: 24 [doi:10.1007/s10549-018-4855-2]

Ettl, J; Quek, RGW; Lee, KH; Rugo, HS; Hurvitz, S; Goncalves, A; Fehrenbacher, L; Yerushalmi, R; Mina, LA; Martin, M; Roche, H; Im, YH; Markova, D; Bhattacharyya, H; Hannah, AL; Eiermann, W; Blum, JL; Litton, JK.

Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial

ANNALS OF ONCOLOGY. 2018; 29(9): 1939-1947 Nº de citas: 110 [doi:10.1093/annonc/mdy257]

Agnelli, G; Becattini, C; Bauersachs, R; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Munoz, A; de Sousa, JA; Torbicki, A; Verso, M; Vescovo, G; Caravaggio Study Investigators.

Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study

THROMBOSIS AND HAEMOSTASIS. 2018; 118(9): 1668-1678 Nº de citas: 104 [doi:10.1055/s-0038-1668523]

Von Hoff, DD; Rasco, DW; Heath, EI; Munster, PN; Schellens, JHM; Isambert, N; Le Tourneau, C; O'Neill, B; Mathijssen, RHJ; Lopez-Martin, JA; Edenfiele, WJ; Martin, M; LoRusso, PM; Bray, GL; DiMartino, J; Nguyen, A; Liu, KJ; Laille, E; Bendell, JC.

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

CLINICAL CANCER RESEARCH. 2018; 24(17): 4072-4080 Nº de citas: 22 [doi:10.1158/1078-0432.CCR-17-3716]

Garcia-Escobar, I; Beato-Zambrano, C; Langa, JM; Vazquez, EB; Portero, BO; Gutierrez-Abad, D; Martin, AJM.

Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(9): 1097-1108 Nº de citas: 13 [doi:10.1007/s12094-018-1835-2]

Aranda, E; Garcia-Alfonso, P; Benavides, M; Ruiz, AS; Guillen-Ponce, C; Safont, MJ; Alcaide, J; Gomez, A; Lopez, R; Manzano, JL; Urena, MM; Sastre, J; Rivera, F; Gravalos, C; Garcia, T; Martin-Valades, JI; Falco, E; Navalon, M; Flores, EG; Tapiador, AMG; Munoz, AML; Barrajon, E; Reboredo, M; Teijido, PG; Viudez, A; Cardenas, N; Diaz-Rubio, E.

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

EUROPEAN JOURNAL OF CANCER. 2018; 101: 263-272 Nº de citas: 66 [doi:10.1016/j.ejca.2018.06.024]

Litton, JK; Rugo, HS; Ettl, J; Hurvitz, SA; Goncalves, A; Lee, KH; Fehrenbacher, L; Yerushalmi, R; Mina, LA; Martin, M; Roche, H; Im, YH; Quek, RGW; Markova, D; Tudor, IC; Hannah, AL; Eiermann, W; Blum, JL.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

NEW ENGLAND JOURNAL OF MEDICINE. 2018; 379(8): 753-763 Nº de citas: 1604 [doi:10.1056/NEJMoa1802905]

Slamon, DJ; Neven, P; Chia, S; Fasching, PA; De Laurentiis, M; Im, SA; Petrakova, K; Bianchi, GV; Esteva, FJ; Martin, M; Nusch, A; Sonke, GS; De la Cruz-Merino, L; Beck, JT; Pivot, X; Vidam, G; Wang, YB; Lorenc, KR; Miller, M; Taran, T; Jerusalem, G.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

JOURNAL OF CLINICAL ONCOLOGY. 2018; 36(24): 2465-2472 Nº de citas: 833 [doi:10.1200/JCO.2018.78.9909]

Carmona-Bayonas, A; Jimenez-Fonseca, P; Echavarria, I; Canovas, MS; Aguado, G; Gallego, J; Custodio, A; Hernandez, R; Viudez, A; Cano, JM; de Castro, EM; Macias, I; Carnicero, AM; Garrido, M; Mangas, M; Mancenido, FA; Visa, L; Azkarate, A; Ramchandani, A; Montes, AF; Longo, F; Sanchez, A; Pimentel, P; Limon, ML; Arias, D; Lavin, DC; Bayona, RS; Cerda, P; Alfonso, PG; AGAMENON Study Grp.

Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry

EJSO. 2018; 44(8): 1191-1198 Nº de citas: 48 [doi:10.1016/j.ejso.2018.03.019]

Girones, R; Morilla, I; Guillen-Ponce, C; Torregrosa, MD; Paredero, I; Bustamante, E; del Barco, S; Soler, G; Losada, B; Visa, L; Llabres, E; Fox, B; Firvida, JL; Blanco, R; Antonio, M; Aparisi, F; Pi-Figueras, M; Gonzalez-Flores, E; Molina-Garrido, MJ; Saldana, J; Spanish Soc Med Oncology SEOM.

Geriatric oncology in Spain: survey results and analysis of the current situation

CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(8): 1087-1092 Nº de citas: 11 [doi:10.1007/s12094-017-1813-0]

Lobo, M; Lopez-Tarruella, S; Luque, S; Lizarraga, S; Flores-Sanchez, C; Bueno, O; Solera, J; Jerez, Y; del Val, RG; Palomero, MI; Cebollero, M; Echavarria, I; Torres, G; Martin, M; Marquez-Rodas, I.

Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit

Journal of Genetic Counseling. 2018; 27(4): 854-862 Nº de citas: 7 [doi:10.1007/s10897-017-0187-3]

Ascierto, PA; Bastholt, L; Ferrucci, PF; Hansson, J; Rodas, IM; Payne, M; Robert, C; Thomas, L; Utikal, JS; Wolter, P; Kudlac, A; Tuson, H; McKendrick, J.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

MELANOMA RESEARCH. 2018; 28(4): 333-340 Nº de citas: 14 [doi:10.1097/CMR.0000000000000455]